Mark Cuban Cost Plus Drug Company Chooses RevSpring for Pharmacy Payment Solution


“We looked at many solutions, but RevSpring offered the most sophisticated and cost-effective payment and tracking solution by far,” said Alexander Oshmyansky, founder and CEO of the Mark Cuban Cost Plus Drug Company.

RevSpring, the leading provider of healthcare engagement and payment solutions, has been selected by the Mark Cuban Cost Plus Drug Company as its payment partner for a new program with U.S. pharmacies. RevSpring, in an innovative application of its PersonaPay™ payment portal, will orchestrate pharmacy billing and give participating pharmacies an efficient way to track prescription sales through its 12-month payments tracking dashboard.

The new program extends the Mark Cuban Cost Plus Drug Company mission to fundamentally change how the pharmacy industry operates by making public health as important as the bottom line. The program is designed to keep drug costs as low as possible for consumers, while delivering more revenue to participating pharmacies.

“We’re delighted to partner with the leading healthcare payments company on our most recent exciting new venture,” said Alexander Oshmyansky, founder and CEO of the Mark Cuban Cost Plus Drug Company. “We looked at many solutions, but RevSpring offered the most sophisticated and cost-effective payment and tracking solution by far. RevSpring also was able to meet our requirements for CRM integration and getting to market quickly.”

“Partnering with Mark Cuban Cost Plus Drug Company on this innovative new program is a perfect fit for RevSpring,” said Valerie Mondelli, chief commercial officer, RevSpring. “We are providing a highly reliable solution leveraging our proven payments technology to ensure successful outcomes for Cost Plus Drug and the pharmacies and consumers they serve. It’s a significant partnership and one that highlights our commitment to innovation, technological excellence, and customer satisfaction.”

PersonaPay enables patients and consumers to pay precisely what they can, when they should, from anywhere. The market-leading solution processes more than $8B in payment transactions annually for providers, payers and specialty healthcare organizations, such as pharmacies. The powerful and flexible platform supports a wide-variety of payment models, including self-service payments, autopay, payment plans, deviceless payments, and staff-assisted payments at the point of service and in the call center. PersonaPay’s robust reporting makes payment processing and reconciliation as effortless for healthcare organizations’ staff as making a payment is for each patient.

About Mark Cuban Cost Plus Drug Company

The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) transparently charges a standard markup on every drug it sells. The costplusdrugs.com online pharmacy launched in January 2022 now carries more than 1,000 prescription products, delivered by mail to thousands of happy customers every day. Cost Plus Drugs is working with health plans, managed-care organizations, pharmacy benefits managers (PBMs) and self-insured employers to bring these same savings to employer-sponsored benefit plans nationwide. If you would like to offer Cost Plus Drugs low cost medications to your company or organization, please contact us at mccpdc.com/payers or visit our LinkedIn page.

About RevSpring

RevSpring leads the market in engagement and payment solutions that inspire patients to participate in and pay for their healthcare. The company has built the industry’s most comprehensive and impactful patient engagement suite, spanning the clinical, operational and payment experience. RevSpring’s OmniChannel communications and payment solutions are backed by behavior analysis, propensity-to-pay scoring, contextual messaging, and user experience best practices. Using proprietary data analytics to tailor the engagement from preservice to post-service, RevSpring improves the patient experience and outcomes for providers, members and patients. To learn more, visit revspringinc.com/healthcare.

Share article on social media or email:

Leave a Reply